CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash Flows from Operating Activities:
Net income	$ 14,594	$ 24,909
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Depreciation and amortization (inclusive of depreciation included in cost of service)	6,138	5,694
Non-cash compensation	7,886	3,273
Amortization and impairment of operating lease right of use assets	8,566	8,622
Loss (gain) on disposal of property and equipment	4	(70)
Loss on personal care divestiture	0	2,186
Deferred income taxes	2,594	2,772
Equity in earnings from equity method investments	(910)	(123)
Amortization of deferred debt issuance costs	248	248
Return on equity method investments	170	1,787
Changes in operating assets and liabilities, net of impact of acquisitions:
Patient accounts receivable	(46,806)	(7,476)
Other current assets	(1,696)	(4,128)
Operating lease right of use assets	(1,042)	(918)
Other assets	155	(111)
Accounts payable	8,652	(3,457)
Accrued expenses	3,029	741
Other long-term obligations	(591)	(28)
Operating lease liabilities	(7,532)	(7,960)
Net cash (used in) provided by operating activities	(6,541)	25,961
Cash Flows from Investing Activities:
Proceeds from the sale of deferred compensation plan assets	21	19
Purchases of property and equipment	(2,670)	(1,350)
Investments in technology assets	(223)	(210)
Investment in equity method investee	(196)	0
Proceeds from personal care divestiture	0	47,787
Acquisitions of businesses, net of cash acquired	0	(350)
Net cash (used in) provided by investing activities	(3,068)	45,896
Cash Flows from Financing Activities:
Proceeds from issuance of stock under employee stock purchase plan	0	816
Shares withheld to pay taxes on non-cash compensation	(617)	(1,308)
Noncontrolling interest contributions	1,764	0
Noncontrolling interest distributions	(756)	(285)
Proceeds from borrowings under revolving line of credit	0	8,000
Repayments of borrowings under revolving line of credit	0	(8,000)
Principal payments of long-term obligations	(8,941)	(55,313)
Purchase of noncontrolling interest	0	(800)
Net cash used in financing activities	(8,550)	(56,890)
Net (decrease) increase in cash, cash equivalents and restricted cash	(18,159)	14,967
Cash, cash equivalents and restricted cash at beginning of period	138,863	54,133
Cash, cash equivalents and restricted cash at end of period	120,704	69,100
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	8,188	6,654
Cash paid for income taxes, net of refunds received	828	352
Cash paid for operating lease liabilities	8,574	8,878
Cash paid for finance lease liabilities	2,236	2,457
Supplemental Disclosures of Non-Cash Activity:
Right of use assets obtained in exchange for operating lease liabilities	7,173	7,083
Right of use assets obtained in exchange for finance lease liabilities	4,326	20,790
Reductions to right of use assets resulting from reductions to operating lease liabilities	168	141
Reductions to right of use assets resulting from reductions to finance lease liabilities	$ 496	$ 369